Cryovials Market worth $0.31 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global cryovials market to grow from $0.24 billion in 2026 to $0.31 billion by 2031, a 5.5% CAGR. Growth is expected to be led by glass cryovials (7.0% CAGR), cell and gene therapy applications (8.0%), academic and research end users (6.5%), and rapid expansion in Asia-Pacific. Demand is being supported by biobanking, advanced therapies, traceable barcoded vials, automation-compatible storage, and stricter cold-chain and sample-integrity requirements.

Analysis

This is not a material earnings driver for TMO, AVTR, GLW, or AZTA: the addressable category is too small and the forecast is a third-party estimate, not evidence of orders or pricing. The investable read-through is instead mix: barcoded, automation-compatible consumables create switching costs when embedded in a biobank’s inventory-management workflow, lifting recurring consumables revenue and potentially supporting gross-margin resilience versus commodity plastic labware. TMO and AZTA have the broadest ability to monetize the workflow through storage, sample-management software, instrumentation, and services; GLW benefits selectively where premium glass is required, but cryovial volumes are unlikely to affect consolidated results.

Near term, there is no reason to chase the named large caps on this release. Over 1-3 months, the relevant catalyst is cell-and-gene-therapy customer utilization and biobank-capex evidence in TMO/AZTA segment commentary, particularly APAC order growth and recurring consumables attach rates. Over 6-18 months, standardization around automated traceability could shift value from standalone vial vendors toward integrated storage/workflow providers, creating pressure on smaller, product-only competitors unless they secure OEM or distribution relationships.

BLFS is the most directional public-market expression because preservation and cryogenic workflow growth can matter to its revenue base, but it is also the highest-risk interpretation: vial demand does not prove therapy-manufacturing volumes, and its economics depend more on commercial cell-therapy throughput than research activity. HVO’s biostorage exposure is operationally relevant but the company’s valuation and results remain principally driven by clinical-trial-services execution; treating a small storage acquisition as a standalone rerating catalyst would be overreach. Consensus may overvalue the nominal growth rate while overlooking procurement fragmentation: academic demand is price-sensitive, whereas premium pricing requires validated commercial therapy workflows.

Key Decisions for Investors

• No incremental position in TMO, AVTR, or GLW on this release; require next-quarter evidence of life-sciences consumables acceleration or APAC bioprocess/biobank order growth before acting. A broad laboratory-spend slowdown would outweigh this niche tailwind.
• Maintain or initiate a modest 6-12 month long AZTA versus short AVTR pair only if AZTA’s sample-management bookings and recurring-storage utilization accelerate; thesis is workflow integration and recurring revenue, not vial unit growth. Exit if AZTA reports weakening utilization or if AVTR’s bioproduction consumables growth reaccelerates enough to close the relative-growth gap.
• Place BLFS on a 1-3 month earnings watch rather than buy immediately. Upgrade to a tactical long only if commercial-therapy customer revenue, preservation-media demand, and gross-margin trajectory confirm throughput growth; downside risk is substantial if cell-therapy launches or manufacturing utilization disappoint.
• For HVO, avoid using cryostorage as the primary long thesis; monitor disclosed storage utilization and cross-selling into pharma clients over the next two reporting periods. The falsifier is lack of organic biostorage growth or integration costs that dilute margins.